No news when Novartis reported earnings( glatopa ) looks like sales very small. The payment from Mylan will not show up till next qtr. And it seams mkt is discounting it already. With all the talk about high drug prices would of expected this as a generic co to hold a little better. Looking for some catalyst to move it higher but do not see any thing on the horizon till late 2017, 2018 if they can deliver.